Bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Oral presentation details efficacy, safety and health-related quality of life data in adult and pediatric patients with sickle cell disease treated with lovo-cel in HGB-206 Group C and HGB-210 ...

Related Keywords

United States ,Philadelphia ,Pennsylvania ,University Of Pennsylvania ,American ,Julie Kanter ,Janetl Kwiatkowski ,Alexisa Thompson ,Richard Colvin ,Perelman School Of Medicine ,Linkedin ,Sickle Cell Disease Center ,Drug Administration ,San Diego Convention Center ,American Society Of Hematology ,University Of Alabama ,Nasdaq ,Exchange Commission ,Thalassemia Center ,Instagram ,Youtube ,Division Of Hematology ,Department Of Pediatrics ,American Society ,Annual Meeting ,Health Related Quality ,Sickle Cell Disease ,Who Have Received ,Gene Therapy ,Sickle Cell ,Improved Quality ,Pediatric Patients ,Post Treatment ,Perelman School ,Iron Burden ,Biologics Licensing Application ,Priority Review ,Prescription Drug User Fee Act ,Neutrophil Engraftment ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,